Latest News - McKesson
Top Corporates Hub
McKesson
Is There An Opportunity With McKesson Corporation's (NYSE:MCK) 37% Undervaluation?
15.02.2026 12:00
Key Insights McKesson's estimated fair value is US$1,482 based on 2 Stage Free Cash Flow to Equity McKesson's US$935...
McKesson (MCK) Valuation Check After Strong Multi‑Period Share Price Momentum
11.02.2026 12:12
McKesson (MCK) is on many investors’ screens after its recent share move, with the stock closing at $935.21 and showing double digit total returns over the past year and the past 3 months. See our latest analysis for McKesson. That recent run, including a 9.9% 7 day share price return and 14.6% 30 day share price return, sits alongside a 1 year total shareholder return of 53.9% and a very large 5 year total shareholder return. Taken together, these figures point to strong momentum rather than...
How Recent Analyst Repricing Is Shaping The Story Behind McKesson (MCK)
11.02.2026 08:13
McKesson’s recent price target reset reflects small but meaningful tweaks to the story the market is telling about the stock. Fair value is moving from about US$942 to roughly US$966, and the discount rate is shifting from 6.956% to 6.978%. Revenue growth assumptions have been updated from 8.47% to 8.05%, hinting that analysts are refining their models around cash flow and risk rather than rewriting the entire outlook. As you read on, you will see how these kinds of adjustments shape the...
5 Insightful Analyst Questions From McKesson’s Q4 Earnings Call
11.02.2026 05:37
McKesson’s fourth-quarter results met Wall Street’s revenue expectations and modestly exceeded consensus for non-GAAP earnings per share, with the market responding positively. Management attributed the growth to robust performance in oncology, expanded biopharma services, and continued momentum in North American pharmaceutical distribution. CEO Brian Tyler specifically highlighted the integration of recent acquisitions such as Florida Cancer Specialists and Prism Vision as meaningful contributo
Morgan Stanley Raises Cardinal Health, Inc. (CAH) Price Target After Strong Q2
09.02.2026 13:05
Cardinal Health, Inc. (NYSE:CAH) is included among 12 Unstoppable Dividend Stocks to Buy According to Analysts. Morgan Stanley boosted its price recommendation on Cardinal Health, Inc. (NYSE:CAH) to $255 from $245 on February 6. The firm kept an Overweight rating on the stock. In a research note, the analyst said the firm updated its view […]
Novo Nordisk sues Hims & Hers over copycat versions of Wegovy drugs; Hims stock plunges 27%
09.02.2026 07:00
Novo is asking the court to permanently ban Hims from selling compounded versions of its drugs that infringe patents, and is seeking to recover damages.
McKesson Corporation Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions
07.02.2026 12:37
It's been a pretty great week for McKesson Corporation ( NYSE:MCK ) shareholders, with its shares surging 14% to US$949...
MCK Q3 Earnings & Sales Top Estimates, 2026 View Up
06.02.2026 15:48
McKesson beats Q3 EPS and revenue estimates, raises fiscal 2026 guidance, and delivers broad-based growth led by oncology, specialty distribution and technology.
US Stock Market Today: S&P 500 Futures Slip As Growth Jitters Offset Softer Yields
06.02.2026 10:07
The Morning Bull - US Market Morning Update Friday, Feb, 6 2026 US stock futures are slightly softer this morning, with E-mini S&P 500 contracts slipping about 0.1%, as investors weigh cooler US bond yields against mixed global growth signals. The US 10 year Treasury yield has dipped below 4.2% after several labor reports came in weaker than expected, which in plain terms means borrowing costs have eased a bit for households and businesses. At the same time, Germany’s exports reached €133.3b...
Equities Fall Intraday as Markets Assess Earnings, Macro Data Ahead of Amazon Results
05.02.2026 19:11
US benchmark equity indexes were lower intraday as traders parsed the latest batch of corporate earn
McKesson Earnings Beat Highlights Oncology Growth And Medical Surgical Separation Plans
05.02.2026 16:11
McKesson (NYSE:MCK) reported a strong fiscal third quarter with double-digit growth in revenue and adjusted EPS. The company expanded its oncology, biopharma services, and North American pharmaceutical distribution operations during the quarter. Management raised full-year earnings guidance and highlighted progress toward separating the medical-surgical business, including transition service agreements. McKesson is preparing for a potential IPO of the medical-surgical unit while integrating...
McKesson (MCK) Is Considered a Good Investment by Brokers: Is That True?
05.02.2026 14:30
According to the average brokerage recommendation (ABR), one should invest in McKesson (MCK). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?
McKesson Q3 Earnings Call Highlights
05.02.2026 08:26
McKesson (NYSE:MCK) reported what executives described as another “strong quarter of results” for its fiscal third quarter of 2026, citing double-digit growth in revenue and adjusted earnings per share and continued momentum across oncology, biopharma services, and North American pharmaceutical dist
MCK Q4 Deep Dive: Oncology, Tech Investments, and Portfolio Focus Drive Growth
05.02.2026 05:41
Healthcare distributor and services company McKesson (NYSE:MCK) met Wall Street’s revenue expectations in Q4 CY2025, with sales up 11.4% year on year to $106.2 billion. Its non-GAAP profit of $9.34 per share was 0.7% above analysts’ consensus estimates.
McKesson Corp (MCK) Q3 2026 Earnings Call Highlights: Strong Revenue Growth and Raised EPS Guidance
05.02.2026 05:04
McKesson Corp (MCK) reports robust financial performance with significant gains in oncology and multi-specialty segments, raising full-year EPS guidance.
Is It Time To Reassess McKesson (MCK) After Its Strong Multi Year Share Price Run?
04.02.2026 11:10
If you are trying to figure out whether McKesson's recent share price puts it at a fair level or not, you are in the right place. McKesson's stock last closed at US$851.12, with returns of 2.0% over the past week, 3.4% over the past month, 3.4% year to date, 41.7% over the past year and 137.5% over three years, while the five year return sits at 374.0%. Recent attention on McKesson has been shaped by ongoing updates around the business and the broader healthcare sector, which help explain...
Earnings To Watch: McKesson (MCK) Reports Q4 Results Tomorrow
03.02.2026 03:08
Healthcare distributor and services company McKesson (NYSE:MCK) will be announcing earnings results this Wednesday after the bell. Here’s what to expect.
McKesson Corporation Completes Divestiture of Norwegian Operations
30.01.2026 13:00
IRVING, Texas, January 30, 2026--McKesson Corporation (NYSE: MCK) announced today that it has closed the transaction to sell its retail and distribution businesses in Norway to NorgesGruppen, a privately owned retail group.
McKesson Corporation Declares Quarterly Dividend
28.01.2026 13:00
IRVING, Texas, January 28, 2026--The Board of Directors of McKesson Corporation (NYSE: MCK) yesterday declared a regular dividend of 82 cents per share of common stock. The dividend will be payable on April 1, 2026, to shareholders of record on March 2, 2026.
Assessing McKesson (MCK) Valuation After Mixed Short-Term Returns And Strong Long-Term Gains
24.01.2026 04:23
Why McKesson (MCK) is on investors’ radar today McKesson (MCK) is drawing attention after recent share price moves, with the stock last closing at US$820.23 and showing mixed returns over the past week, month and past 3 months. See our latest analysis for McKesson. While the 7 day share price return of 2.41% and the 30 day return of 0.75% suggest some recent cooling in momentum around the latest close at US$820.23, the 1 year total shareholder return of 39.24% and 5 year total shareholder...